
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
A call has come from an emergency medicine physician who wishes to transfer a 12-year-old boy with an acute onset of ataxia.






